{
  "guideline": {
    "id": "PA166182844",
    "name": "Annotation of DPWG Guideline for simvastatin and SLCO1B1",
    "source": "DPWG",
    "version": 13,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182844",
    "relatedChemicals": [
      {
        "id": "PA451363",
        "name": "simvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299084",
      "name": "Recommendation PA166299084",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061447,
        "html": "<ol>\n<li>Choose an alternative.\nConsider any additional risk factors for statin-induced myopathy.\nAtorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.\nRosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.\nFluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n</ol>\n"
      },
      "implications": [
        "When using simvastatin 80 mg/day, the risk of myopathy is increased 30-fold to 18% and the risk of severe myopathy is increased 48-fold to 12%. When using 40 mg/day, this risk is increased 7-fold to 1% and 11-fold to 0.68% respectively. The gene variation leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects."
      ],
      "lookupKey": {
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299083",
      "name": "Recommendation PA166299083",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061446,
        "html": "<ol>\n<li>Choose an alternative.\nConsider any additional risk factors for statin-induced myopathy.\nAtorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.\nRosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.\nFluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n<li>If an alternative is not an option:\n<ol>\n<li>Avoid simvastatin doses exceeding 40mg/day.</li>\n<li>Advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n</li>\n</ol>\n"
      },
      "implications": [
        "When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39% and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects."
      ],
      "lookupKey": {
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299085",
      "name": "Recommendation PA166299085",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061448,
        "html": "<p>The guideline does not provide a recommendation for atorvastatin in patients with the <em>SLCO1B1</em> 521 TT genotype.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of the SLCO1B1 521 TT genotype on simvastatin."
      ],
      "lookupKey": {
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2023-12-19-10-38"
}